Carol Wiesner
Family · Fort Worth, TXNPI 1528832490
Payments from drug & device makers
Across 192 payments — averaging $22.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$400
- Corcept Therapeutics$390
- Lilly USA, LLC$384
- BETA Bionics, Inc.$304
- Mannkind Corporation$272
- Novo Nordisk$264
- plus $2K from 29 others
What the payments were for
- Food & beverage$4,355100%
- Education$10%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 19 | $400 |
| Corcept Therapeutics | 14 | $390 |
| Lilly USA, LLC | 21 | $384 |
| BETA Bionics, Inc. | 6 | $304 |
| Mannkind Corporation | 10 | $272 |
| Novo Nordisk | 14 | $264 |
| Boehringer Ingelheim | 11 | $230 |
| Xeris Pharmaceuticals, Inc. | 12 | $214 |
| Madrigal Pharmaceuticals | 6 | $187 |
| Sequel Med Tech, LLC | 7 | $147 |
| Sanofi-aventis U.S. LLC | 5 | $136 |
| Tandem Diabetes Care, Inc. | 5 | $131 |
| Ascendis Pharma Endocrinology Inc | 5 | $129 |
| Dexcom, Inc. | 6 | $121 |
| Recordati_rare_diseases_inc. | 5 | $111 |
| Verity Pharmaceuticals Inc. | 4 | $99 |
| Novartis | 5 | $97 |
| Insulet Corporation | 3 | $93 |
| Chiesi USA, Inc. | 4 | $89 |
| Esperion Therapeutics, Inc. | 5 | $82 |
| AbbVie | 5 | $81 |
| Neurocrine Biosciences, Inc. | 2 | $59 |
| Avvisto Therapeutics, LLC | 3 | $46 |
| Cequr Corporation | 2 | $38 |
| Bayer | 2 | $35 |
| Ascensia Diabetes Care US Inc. | 2 | $35 |
| Radius Health, Inc. | 1 | $33 |
| IBSA Pharma Inc. | 1 | $25 |
| Globus Medical | 1 | $22 |
| Rhythm Pharmaceuticals, Inc. | 1 | $19 |
| Amphastar Pharmaceuticals, Inc. | 1 | $19 |
| Enterra Medical, Inc. | 1 | $18 |
| Astellas Pharma US Inc | 1 | $17 |
| Tolmar, Inc. | 1 | $16 |
| Antares Pharma, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,356 in reported general payments places this provider in the 90th percentile of 15,456 family providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 64 | $79,519 |
| OzempicSemaglutide | 41 | $68,216 |
| JardianceEmpagliflozin | 17 | $21,784 |
| Tresiba Flextouch U-200Insulin Degludec | 11 | $16,000 |
| Tresiba Flextouch U-100Insulin Degludec | 13 | $9,044 |
| Glimepiride | 30 | $420 |
| Pioglitazone Hcl | 11 | $401 |
| Levothyroxine Sodium | 25 | $317 |
| Metformin Hcl ErMetformin Hcl | 20 | $195 |
| Metformin Hcl | 14 | $158 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $384 | $79,51964 claims |
| Novo NordiskOzempic | $264 | $68,21641 claims |
| Boehringer IngelheimJardiance | $230 | $21,78417 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 15,456 family providers in Texas.
Other family in Fort Worth
- Laura MoeFort Worth$158K
- Julie TaylorFort Worth$63K
- Ryan BourgeoisFort Worth$37K
- Lashonda CraneHouston$3.4M
- David WeirDallas$959K
- Luba YammineHouston$479K
- Robin BeachHouston$428K
- Nirupama JeromeAustin$418K
- April LopezMcAllen$417K
- Linda MercadoHouston$211K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.